Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing
about
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsAntimicrobial Peptides Targeting Gram-Positive BacteriaAntibiotics in the clinical pipeline at the end of 2015.Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Advances in MRSA drug discovery: where are we and where do we need to be?Recent advances in the synthesis of new glycopeptide antibiotics.Inhibitors targeting on cell wall biosynthesis pathway of MRSA.Current and prospective treatments for multidrug-resistant gram-positive infections.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Glycopeptide antibiotics: back to the future.Natural product and natural product derived drugs in clinical trials.Oritavancin: A Long-Half-Life Lipoglycopeptide.Oritavancin: a review in acute bacterial skin and skin structure infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Old and New Glycopeptide Antibiotics: Action and Resistance.Oritavancin: a long-acting antibacterial lipoglycopeptide.Targeting bactoprenol-coupled cell envelope precursors.Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.Targeting a cell wall biosynthesis hot spot.Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.Single Intravenous Dose of Oritavancin for the Treatment of Gram-positive Acute Bacterial Skin and Skin Structure Infections: Summary of Safety from the Phase 3 SOLO studies.Study on synthesis and bioactivity of biotinylated emodin.Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function.Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in h
P2860
Q26772897-C203A52A-037A-4176-BC1E-A4950045FE2BQ26799701-660E982B-2895-458A-8640-11B1E18771F4Q28077888-D9E50548-7915-43FA-A5E6-F9333EB8D3AFQ30249262-C94D9D17-99E2-42ED-97D9-7649FB3C64CBQ34448260-E828AB0C-0325-4BD8-B022-EF06D30D1C92Q35065786-349FC2C0-6CC9-4BA6-B78B-2859CFB13896Q37112508-AF5AA7C8-85E6-46E8-9611-3FF1C0F89F24Q37914730-D31FAF4C-A0E5-45B3-B6BB-94EE6FBAC2F0Q38035171-374B74A4-65C8-4D66-AB04-CAD38A9431C2Q38123255-23DBE46D-8CCE-435D-83A0-889DE849DD82Q38233471-C2606A04-7960-4B4E-A725-47ED016789B0Q38239460-589BAC87-C7E6-47FB-9043-9353D05B463FQ38247457-CF2A5475-CDF3-4FF6-8692-811691F15094Q38434265-8AD126F7-9906-4645-B203-2A9A9A72933CQ38606618-D53CEA87-B942-489F-8FE7-71500AD07536Q38646905-CF1694F0-B4D0-4CF6-88ED-9258930A1F82Q38792892-22494479-F12A-4A07-A62C-CA396E429145Q38830176-90DECEE8-280E-40D4-A989-ACC9D702A9D6Q38919751-10640F31-3003-4B93-9E05-6A39A3AD4783Q39373932-5BD61B33-9D8C-4C20-9A25-C035A4255CC7Q39413308-246808B6-636B-4F30-B998-564FC4160639Q40719299-215DCB4D-9B83-403C-B1CE-98A0C5038F8FQ42530056-E6B98C65-5AD0-465E-B360-DE2D725021E0Q47236751-55124965-0EF9-4A26-98FC-A3DF74FB79E1Q49874661-C5A3A696-1162-485A-834A-692825DFF6AAQ50927018-6CBA9161-4E4A-4372-A250-08F57000E946Q52680606-FE3024DB-1BC8-45CD-92A6-D9D6BB0B7856Q53779482-7079674E-8025-4E13-8D09-5F9D0661C069Q55711857-327FCF1C-7555-4286-81D8-A45BAE3AE24CQ58573611-0158278F-4BCD-4AE7-9126-3C1FCA72E123
P2860
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@ast
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@en
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@nl
type
label
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@ast
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@en
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@nl
prefLabel
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@ast
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@en
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@nl
P2093
P2860
P3181
P356
P1476
Oritavancin disrupts membrane ...... effect rapid bacterial killing
@en
P2093
Adam Belley
Francis F Arhin
Geoffrey A McKay
Ibthihal Fadhil
Ingrid Sarmiento
Sylvain Beaulieu
Thomas R Parr
P2860
P304
P3181
P356
10.1128/AAC.00760-10
P407
P50
P577
2010-09-27T00:00:00Z